Lexington Herald Leader Logo

Monthly shot could be the ‘next revolution’ in HIV therapy | Lexington Herald Leader

×
  • E-edition
  • Home
    • All News
    • Business
    • Communities
    • Counties
    • Crime
    • Education
    • Lexington
    • Local
    • Most Wanted
    • Nation/World
    • News Photos
    • News Videos
    • Politics
    • Searchable Databases
    • State
    • Watchdog
    • Columns
    • Tom Eblen
    • All Sports
    • UK Sports
    • College Sports
    • Next Cats Recruiting
    • High School
    • Horses
    • Kentucky Speedway
    • Lexington Legends
    • Reds
    • MLB
    • NBA
    • NASCAR
    • NFL
    • Sports Photos
    • Sports Videos
    • Columns
    • John Clay's Columns
    • Mark Story
    • Next Cats Recruiting
    • All UK Sports
    • Next Cats Recruiting
    • Baseball
    • Basketball - Men
    • Basketball - Women
    • Recruiting
    • Ex-Cats
    • Football
    • UK Photos
    • UK Videos
    • More UK Sports
    • Columns
    • John Clay's Blog
    • Mark Story
    • Politics
    • Elections
    • All Entertainment
    • Books
    • Celebrities
    • Comics
    • Puzzles & Games
    • Events Calendar
    • Horoscopes
    • Movies
    • Music
    • Restaurants
    • Stage & Dance
    • TV
    • Visual Arts
    • Entertainment Photos
    • Entertainment Videos
    • News Blogs
    • Kentucky Weather
    • Photo Archive
    • Sports Blogs
    • John Clay's Blog
    • High School
    • UK Football
    • UK Men's Basketball
    • UK Women's Basketball
    • Lexington Legends
    • Entertainment Blogs
    • Walter Tunis on Music
    • All Opinion
    • Editorials
    • Joel Pett
    • Letters to the Editor
    • National Columnists
    • Op-Ed
    • Submit a Letter
    • All Living
    • Celebrations
    • Family
    • Fashion
    • Food & Drink
    • Fru-Gal: Deb Morris
    • Health & Medicine
    • Home & Garden
    • Paul Prather
    • Religion
    • Travel
    • Readers' Choice
    • Kentucky Obituaries
    • Obituaries in the News
    • Submit an Obituary
    • Customer Service
    • Contact Us
    • About Us
    • E-edition
    • Page Reprints
    • Photo Reprints
    • RSS Feeds
    • Special Sections
    • Site Information
    • Advertise With Us
    • Archives
    • Mobile
    • Mobile Apps & eReaders
    • Newsletters
    • Social
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • Google+
    • Today's Circulars
    • Classifieds
    • Jobs
    • Cars
    • Homes
    • Homeseller
    • Legal Notices
  • Place an Ad
  • Mobile & Apps

Health & Medicine

Monthly shot could be the ‘next revolution’ in HIV therapy

By Ariana Eunjung Cha

The Washington Post

    ORDER REPRINT →

July 26, 2017 04:12 PM

HIV/AIDS is no longer the death sentence it once was, but maintaining the strict regimen required to keep the virus at bay — one or more pills daily — still poses a major challenge to many people who are infected. Adherence is low among some populations, given the effort that is required to obtain, keep and store the medications.

That may soon change. Earlier this week, scientists reported an important advance in the development of a long-acting antiretroviral shot. According to an international study involving 309 patients, an injection that combines two drugs, cabotegravir and rilpivirine, appears to be as safe and effective at suppressing HIV as the daily oral regimen.

Writing in the Lancet, David Margolis of ViiV Healthcare, called it “the next revolution in HIV therapy.”

In the study, which was conducted at 50 centers in the United States, Germany, Canada, Spain, France and Germany, patients were begun on 20 weeks of daily oral medication. Once that medication had brought their viral loads down, they were given the shots as a “maintenance therapy.” Some were given the shot at four-week intervals and others at eight-week intervals. A control group continued to take the pills.

Sign Up and Save

Get six months of free digital access to the Lexington Herald-Leader

SUBSCRIBE WITH GOOGLE

#ReadLocal

The majority of the patients tolerated the therapy well, though nearly everyone reported some mild to moderate pain at the injection site. The rates of some adverse events like headaches were similar across all three groups.

At 96 weeks, 84 percent of the patients in the oral medication group were able to keep their viral load suppressed, compared with 87 percent of the four-week shot group and 94 percent of the eight-week shot group.

The shots could revolutionize patient care in places like Africa, where it can be difficult for many people to get to a pharmacy regularly. But Mark A. Boyd, a professor at the University of Adelaide, wrote in a commentary piece accompanying the main article that there are trade-offs with both a pill and injection.

In his home country of Australia, for instance, he said people can get up to a six-month supply for antiretroviral pills. For them, going to a health care provider for a monthly shot actually may be less convenient.

“This is compounded by the fact that health care systems are generally not configured to facilitate regular, recurrent injections in a timely and convenient way to people who are well,” he wrote. “Changing this will take innovation, political will and time.”

Studies of some medications have shown dramatic increases in compliance and length of use with longer-acting versions versus daily pills. For osteoporosis drugs, for example, one study found compliance was just 38.6 percent for daily oral medications for a year and 77.7 percent for a monthly oral dose.

But for other therapies, a longer-acting formula doesn’t seem to make a difference. While it has been difficult to compare compliance rates for birth control options because of varying methodology, one study involving postpartum teenagers found no difference in the rates (68 percent) at which they stopped using a monthly injectable and the pill.

  Comments  

Videos

5 things to avoid flushing down your toilet

Woman tells her story of DUI arrest to prevent others from drinking and driving

View More Video

Trending Stories

Sayre School to honor ‘two remarkable young men’ killed in car crash.

February 18, 2019 12:52 PM

Curse of Saratoga strikes again? Another Chevy Chase restaurant closes in Lexington.

February 19, 2019 12:19 PM

‘Their hearts showed through their smiles.’ Funeral set for Lexington brothers killed in crash.

February 19, 2019 05:50 PM

Kentucky students need border wall before a new middle school, Sen. Lindsey Graham says.

February 18, 2019 11:41 AM

With Kentucky’s Travis possibly sidelined, Cal challenges other ‘bigs’

February 20, 2019 01:39 AM

Read Next

US mining sites dump 50M gallons of fouled wastewater daily

Health & Medicine

US mining sites dump 50M gallons of fouled wastewater daily

By MATTHEW BROWN Associated Press

    ORDER REPRINT →

February 20, 2019 11:29 AM

U.S. public records show that millions of gallons of water containing arsenic, lead and other toxic metals flow from contaminated mining sites into lakes and stream.

KEEP READING

Sign Up and Save

#ReadLocal

Get six months of free digital access to the Lexington Herald-Leader

SUBSCRIBE WITH GOOGLE

MORE HEALTH & MEDICINE

Health & Medicine

NY man warns others to quit smoking in his obituary

February 20, 2019 11:27 AM

Health & Medicine

3rd child flu death reported in Massachusetts

February 20, 2019 11:01 AM

Health & Medicine

Mexico seizes more than 1,300 pounds of cocaine at sea

February 20, 2019 10:54 AM

Health & Medicine

Bills would prohibit Florida abortions after fetal heartbeat

February 20, 2019 10:02 AM
Trouble at CVS Health long-term care business weighs heavily

Health & Medicine

Trouble at CVS Health long-term care business weighs heavily

February 20, 2019 09:16 AM

Health & Medicine

Florida Highway Patrol trooper dies during training

February 20, 2019 08:40 AM
Take Us With You

Real-time updates and all local stories you want right in the palm of your hand.

Icon for mobile apps

Lexington Herald Leader App

View Newsletters

Subscriptions
  • Start a Subscription
  • Customer Service
  • eEdition
  • Vacation Hold
  • Pay Your Bill
  • Rewards
Learn More
  • About Us
  • Contact Us
  • Newsletters
  • News in Education
  • Archives
Advertising
  • Contact Us
  • Place a Classified Ad
  • Local Deals
  • Digital Solutions
  • Media Kit
Copyright
Privacy Policy
Terms of Service


Back to Story